chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a nurse practitioner concerning a female between 16-20 years of age, who on an unspecified date was vaccinated with GARDASIL vaccine (yeast). The nurse practitioner reported that within the last 4-6 months the patient had experienced fainting and dizziness after receiving GARDASIL vaccine (yeast). It is unclear if the fainting occurred after all three dose or not. At the time of the report the patients had recovered; she was fine before leaving the office after receiving the vaccine. The patient did not seek medical attention. This is one of several reports received from the same source. Attempts are being made to obtain additional identifying information to distinguish the individual patients. Additional information has been requested.
Reddened area in upper right arm. Warm to touch. Site is beneath injection site.
Arm below injection sight started to get read quarter size to start, 10 am by the end of the day it had grown to 3 inches in diameter, by the following morning the amount of heat was still the same and it was still growing in size.  Seen the dermatologist the second day recommended for me to take Benadryl and Claritin. By the second day of taking  the combination of Benadryl and Claritin it stopped growing and the heat went away. Still taking it will be seeing my dermatologist again this Friday
Ten weeks after getting second Moderna she developed blood clots in leg and lungs. Taking Elequist at this time and doing better.
I have a numbness on the bottom on my feet and travels up to the middle of my leg. In my left leg it had gone as far as my knee. I also have a stiffness in both ankles. On the left leg it has gone down to the middle of my foot. The right leg it has gone down to my ankle.
Moderate pain at vaccine site, swollen lymph nodes in throat and left underarm, widespread body aches, headache, mild nausea
It was reported that a 2 year old male patient received a ProHIBit vaccination on 03/30/00. The same day the patient developed hives and angioedema. The patient was treated with Epinephrine, Benadryl, Tagamet, and Pedispred.
Nov 19, I had a slight cold and a terrible cough and no fever, tired and runny nose and got tested positive at the doctor's office. I had had the infusion the next day. Never lost taste and smell. I still have a runny nose and little cough and tired.
Pt swelled up at site of injection (immediately). However, he did not feel any pain or itching. I followed up with pt and he was doing fine. Reported a little bruising that went away and no other symptoms.
Change in menstrual cycle. Prior to being vaccinated, my menstrual cycles averaged 80 days. Since being vaccinated my cycles have averaged 40 days.
Patient received second dose Covid Vaccine 15 days after her first Covid Vaccine. Staff oversaw the date in which patient received first dose. No adverse reaction shown at the time of injection. Provider notified patient vacine was given too early.
Patient passed out  shortly after shot. He fell off chair and hit head on floor. Had a little blood on top of head. He drank water , OJ and had chips and felt better. He did not want me to call the squad. He was able to stand and was coherent. He  wanted to walk/ drive himself home.
SUSPECTED COVID-19 INFECTION; METAL TASTE IN MOUTH; FEELING FAINT; FLUSHING; This spontaneous report received from a patient via another pharmaceutical company (Pfizer) concerned a 62 year old White female of an unspecified ethnicity. The patient's height, and weight were not reported. Patient was not pregnant at time of vaccination. The patient's past medical history included: penicillin allergy. The patient had previously received first dose of covid-19 vaccine ad26. cov2. s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 1855194, expiry: unknown) dose was not reported, 1 in total was administered on 03-Nov-2021 to left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26. cov2. s (dose number in series 1). The patient received second dose of covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin not reported, batch number: 1805018, expiry: unknown) dose was not reported, 1 in total was administered to left arm on 13-MAR-2022 for covid-19 prophylaxis. Age at time of vaccination 62 years old. No concomitant medications were reported. On an unspecified date, the patient experienced suspected covid-19 infection (dose number in series 2). On 21-NOV-2022, the patient was treated with non-company suspect drug Paxlovid (route of administration, batch number and expiry were not reported) dose and frequency were not reported for covid-19 treatment. On 21-NOV-2022 19:45, the patient experienced metal taste in mouth, was feeling faint, and flushing (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable and with Paxlovid was not reported. The outcome of the suspected covid-19 infection, metal taste in mouth, feeling faint and flushing was not reported.  This report was non-serious.
pt recv vax & exp inj site rxn following receipt of tetramune;no other details were available @ the time of this report;
developed a severe rash diagnosed as serum sickness 10 days after my 2nd vaccine dose; My 22 month old daughter, whom I am breastfeeding; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the parent.  A 22 month-old female patient was exposed to bnt162b2 (BNT162B2), transmammary administered in arm left, administration date 10Sep2021 11:00 (Lot number: EW0186) as dose 1, single for covid-19 immunisation. The mother of the patient was 32 years old at the time of vaccination. The patient had no relevant medical history. Date of last menstrual period of the mother: 29Mar2021. The mother was 23 weeks pregnant at the time of exposure to bnt162b2. The mother was 23 weeks pregnant at the event onset. The mother is expected to deliver a baby(s) on 27Jan2022. The patient's concomitant medications were not reported. The following information was reported: EXPOSURE VIA BREAST MILK (non-serious) with onset 10Sep2021, outcome "unknown", described as "My 22 month old daughter, whom I am breastfeeding"; RASH (non-serious) with onset 20Sep2021, outcome "unknown", described as "developed a severe rash diagnosed as serum sickness 10 days after my 2nd vaccine dose".  No follow-up attempts are possible. No further information is expected.
Continual feeling of pin prick, itchiness, and pain at site of injection, even weeks later (today is more than a month later).
Within 1 minute of receiving the vaccine, patient reported not feeling well. Administrating technician called for assistance from the pharmacist. Patient was breathing but was unresponsive. Pharmacist instructed store manager (also on scene) to call 911, and gently laid the patient on the floor. Within one minute the patient became responsive, and remained on the floor per instructions received from 911 over the phone. Shortly thereafter EMS arrived and assessed the patient. Patient refused to go with EMS for further medical assistance. She agreed to stay in a chair in front of the pharmacy for further observation for 30 minutes. After the 30 minutes lapsed, patient left the store under her own volition.
arm (left and right) numbness, hand numbness, numbness in face, loss of voice and a bad ough
Patients mother stated that patient had plum size ball on leg where injection was given on both the right and left thigh. (anterolateral) She tried to massage and place heat but it stayed that size throughout the weekend and is slowly going down.  Denies any redness or warm to touch now.  Patients mother did state she noticed a hive at the injection site.
Swollen lips; her eyelids and lips were swollen; allergic reaction to the first dose; This spontaneous case was reported by an other health care professional and describes the occurrence of LIP SWELLING (Swollen lips), EYE SWELLING (her eyelids and lips were swollen) and ALLERGY TO VACCINE (allergic reaction to the first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Histamine intolerance, Multiple sclerosis and Immunocompromised.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LIP SWELLING (Swollen lips), EYE SWELLING (her eyelids and lips were swollen) and ALLERGY TO VACCINE (allergic reaction to the first dose). At the time of the report, LIP SWELLING (Swollen lips), EYE SWELLING (her eyelids and lips were swollen) and ALLERGY TO VACCINE (allergic reaction to the first dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient had anaphylactic reaction to tetanus toxoid and the shingles vaccine. The patient have pre serious allergic reactions so, to manage the allergic reaction she received five injections in a step wise manner three in one arm and two in another in 15-minute intervals. After the third injection, she did feelsome tingling in her arm, but it resolved on its own. No concomitants were reported. No treatment drugs were reported.
This case was reported by a consumer via call center representative and described the occurrence of rash in a 60-year-old female patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 11th May 2018, less than a year after receiving SHINGRIX, the patient experienced rash. On an unknown date, the outcome of the rash was unknown. The reporter considered the rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. In morning patient experienced rash on her thighs and her stomach and later in the afternoon she experienced rash across her back. The patient's symptoms were still unchanged. The patient wanted to follow up with their health care provider for further information.
Reported to us 11/13/02. Received Td 11/5/02 left deltoid. Started with rash over left shoulder on 11/8/02. States lips and face also swelled and turned red. Denied any problems breathing at that time. Used hydrocortisone cream. Better today. Patient to continue cream on rash; seek attention if breathing problems develop. Instructed to inform other health care providers of reaction. She has a scheduled MD appointment on 11/15/02.
erythema & swelling of lt deltoid x 1wk;4x10cm oval;tx pred & atarax;
Hard knot under the skin 1 inch in diameter, warm to touch 6 days post administration day.
throat tightening, SOB, pallor, diaphoresis, lethargy; epi given w/immed relief;
Patient reports feeling symptoms oflow blood sugar the day after thevaccination; strange taste; Strange smell; This is a spontaneous report from a non-contactable pharmacist. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 15Apr2021 at 08:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included gastroesophageal reflux disease (GERD). The patient did not have a history of allergies to medications, food, or other products. Concomitant medications included omeprazole (PRILOSEC) from unknown date and for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021, the patient experienced strange taste and smell which started about 24 hours after the vaccine and lasted for about 48 hours. On 16Apr2021, the patient reported feeling symptoms of low blood sugar the day after the vaccination, despite having eaten normally. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events strange taste and smell was resolved on 17Apr2021, after the duration of 24 hours (and 48 hours after vaccination). The clinical outcome of the event feeling symptoms of low blood sugar was resolved on an unknown date at Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
but her dizziness is terrible/she'd rather be dizzy than get covid; she states that now she is dizzier and her eye watch stated her walking is so unsteady and she is at fall risk/she can tell she is like that all by her self.; head injuries; and her arm was awfully sore for a couple days but now is ok; This spontaneous case was reported by an other health care professional and describes the occurrence of DIZZINESS (but her dizziness is terrible/she'd rather be dizzy than get covid), GAIT DISTURBANCE (she states that now she is dizzier and her eye watch stated her walking is so unsteady and she is at fall risk/she can tell she is like that all by her self.), HEAD INJURY (head injuries) and MYALGIA (and her arm was awfully sore for a couple days but now is ok) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C210) for COVID-19 vaccination.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (COVID-19 VACCINE JANSSEN) for COVID-19 vaccination.    The patient's past medical history included Drug allergy.   On 09-Apr-2021, the patient started COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (COVID-19 VACCINE JANSSEN) (unknown route) at an unspecified dose. On 08-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (but her dizziness is terrible/she'd rather be dizzy than get covid), GAIT DISTURBANCE (she states that now she is dizzier and her eye watch stated her walking is so unsteady and she is at fall risk/she can tell she is like that all by her self.), HEAD INJURY (head injuries) and MYALGIA (and her arm was awfully sore for a couple days but now is ok). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at a dose of 1 dosage form and MECLIZINE [MECLOZINE] for Adverse event, at a dose of 1 dosage form. At the time of the report, DIZZINESS (but her dizziness is terrible/she'd rather be dizzy than get covid), GAIT DISTURBANCE (she states that now she is dizzier and her eye watch stated her walking is so unsteady and she is at fall risk/she can tell she is like that all by her self.) and HEAD INJURY (head injuries) outcome was unknown and MYALGIA (and her arm was awfully sore for a couple days but now is ok) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.
pt devel fever & fussiness 3 days p/vax;also devel pimple like nodes on rt eye lid;cont to have eye problems mo later;has 1-2 sty-like protrusions on rt eye & is now devel same on lt eye;
Started with local reaction at inj. site- bumpy, itchy rash. Now 6" in diameter red area. Tender has improved with BENADRYL.
1st shot 2019, still need 2nd dose; This case was reported by a consumer via interactive digital media and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (1st dose received in 2019).   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The patient did not receive the 2nd dose of Shingrix till the time of reporting, which led to incomplete course of vaccination. The reporter wanted to know do he/she have to start over and still need second dose. The follow up would not possible as no contact details were available.
Mild swelling (2" x 1" area) near injection site on left deltoid area; noticeable redness and warm to touch; noticeable redness and warm to touch; This is a spontaneous report from a contactable consumer (patient) reported for herself that a 52-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL1284) via an unspecified route of administration at left arm (deltoid), on 06Jan2021 14:15 at single dose for COVID-19 immunization. Medical history included sulfa allergy. Patient was not pregnant at the time of vaccination. Patient did not have COVID prior vaccination. Concomitant medication included tocopherol (VITAMIN E). Patient did not receive other vaccine in four weeks. Patient experienced mild swelling (2" x 1" area) near injection site on left deltoid area, noticeable redness and warm to touch, appeared 8 days after injection on 14Jan2021 05:00. No treatment received. No COVID tested post vaccination. Outcome of the events was not recovered.
felt a little bit dizzy,  I do feel lightheaded; my blood pressure was way down, it fell down to 99/53, has gone as low as 89/54; felt like I was running a fever; sharp pains shooting through my head,; This case was reported by a consumer via call center representative and described the occurrence of dizziness in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Zostavax (received on an unknown date) and Shingrix (1st dose received on an unknown date). Concurrent medical conditions included atrial fibrillation and hypertension. Concomitant products included metoprolol, apixaban (Eliquis), lisinopril and flecainide.   On 26th April 2022, the patient received the 2nd dose of Shingrix. On 26th April 2022, less than a day after receiving Shingrix, the patient experienced headache. On an unknown date, the patient experienced dizziness, low blood pressure and fever. On an unknown date, the outcome of the dizziness, fever and headache were recovered/resolved and the outcome of the low blood pressure was not recovered/not resolved.   It was unknown if the reporter considered the dizziness, low blood pressure, fever and headache to be related to Shingrix.     Additional Information: GSK Receipt Date: 5-May-2022 Reporter's comments: This case was reported by the patient. The patient received 2nd dose of Shingrix and in night of 26th April, the patient experienced sharp pains shooting through head which was minor. Less than 2 weeks after vaccination, the patient felt like was running a fever but did not take temperature. The patient felt a little bit dizzy. The patient had been on blood pressure medicines for like 40 years. The patient took blood pressure and blood pressure was way down and the patient thought it would probably in a day or two be fine but it was staying down. The patient talked to the heart doctor and they actually cut one of medications flecainide in half. The blood pressure was staying low and sometimes it goes low fairly fast. The highest it had been since the patient had the Shingrix shot was 129/64. Normally with all medications the patient would stay in the low 120/50. Within 2 hours after taking medication it came down to 107 which usually it was 120 then it fell down to 99/53 and it had gone as low as 89/54.  In the morning of date of reporting, the patient took it at 6:05 and it was 114/54 and the patient still had not taken medicine. At 8:39 it was 108/58. The patient's pulse was where they want it in the 50's low 60's. The oxygen was staying up. The blood pressure always stayed the same previously. At times the patient felt lightheaded. The call center representative unable to ask further questions such as date of birth, MD contact information because call ended abruptly when reporter received an inbound phone call from his doctor's office.
Patient was found passed away on Wednesday morning. Severe stomach upset seemed to be happening. Signs of upset stomach and diarrhea were evident. I don't believe patient told anyone they were sick.
Abdominal pain for days, hallucinations, uncontrolled urination for days, fatigue, weakness, cognitive difficulties
Treatment of COVID-19; Treatment of COVID-19; Name of Drug as Reported: Pfizer / BioNTech, Dose Number: 3; Name of Drug as Reported: Moderna, Dose Number: 4; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 05Mar2021 as dose 1, single (Lot number: EN6205), in right arm, on 02Apr2021 as dose 2, single (Lot number: ER8737), in right arm and on 17Oct2021 as dose 3 (booster), single (Lot number: 3014584) at the age of 60 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 26Apr2022 as dose 4 (booster), single (Lot number: 005m21A), in right arm and on 10Sep2022 as dose 5 (booster), single (Lot number: A57143C), in right arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: BENAZEPRIL, start date: 01Sep2020. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 26Apr2022, outcome "unknown", described as "Name of Drug as Reported: Pfizer / BioNTech, Dose Number: 3; Name of Drug as Reported: Moderna, Dose Number: 4"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid from 02Oct2023 to 06Oct2023.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300329549 same patient, different drug and event;
Large Red Round Rash, around injection site about 5-6 inches in diameter. Not raised.
Pt reported shaking, teeth chattering, throat felt like it was closing then tingling approximately 20 minutes after inj. Taken to ER by ambulance where she was given Epinephrine and IV BENADRYL. Pt reports she never lost consciousness.
Patient entered the room and sat down on the exam table to receive his second dose of the Pfizer COVID-19 vaccination. He seemed nervous and explained that he hates needles. At 3:28pm vaccine was administered in his left deltoid muscle after cleaning the site with an alcohol prep. He sat in the chair while I administered the vaccine to his significant other. While I was filling out their paperwork and vaccination cards, at approximately 3:38pm the patient stated "I feel dizzy." He then proceeded to feel nausea, dry heave, become pale, and diaphoretic. He was given an emesis bag which he never vomited. I checked his BP with it being 85/65. He appeared to be having a vasovagal reaction. After about 5 minutes he stated he was feeling much better. His skin appeared warm and pink again and he was able to drink water. Around 3:50, he proceeded to exit the clinic into the store with his significant other stated "I feel much better." He also stated that he has had similar reactions before with other injections and phlebotomy draws.
Rash developed from 1/17/10 to 1/19/10 blanching discrete rash starting head working down to face.
Pt vacc. w/ PEDVAC/DTP/OPV developed unusual high pitched cry & prolonged crying x1hr; pain to touch, swelling, redness in HIB leg; DTP leg was red & swollen.